Breaking Finance News

Amarin (NASDAQ:AMRN) target bumped up to $5.00, released a ratings update earlier today by Citigroup

Just yesterday Amarin (NASDAQ:AMRN) traded 1.33% higher at $3.00. Amarin’s 50-day moving average is $2.99 and its 200-day average is $2.41. With the last close up 26.39% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. Trade Volume was down over the average, with 2,660,919 shares of AMRN changing hands under the typical 3,942,350

Citigroup bumped up the target of Amarin (NASDAQ:AMRN) to $5.00 indicating a possible upside of 0.67%.

Previously on 10/05/2016, Cantor Fitzgerald reported about Amarin (NASDAQ:AMRN) raised the target price from $0.00 to $6.00. At the time, this indicated a possible upside of 0.88%.

Recent Performance Chart


Amarin has with a one year low of $1.24 and a one year high of $3.46 and has a market capitalization of $0.

A total of 2 brokerages have issued a ratings update on Amarin. One brokerage rating the company a strong buy, two brokerages rating the company a buy, one brokerage rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $8.00.

General Company Details For Amarin (NASDAQ:AMRN)

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. The Company operates in the business segment of development and commercialization of Vascepa. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its Distributors, that in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. The Company markets Vascepa in the United States.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.